Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In his recent editorial commenting on the Combining Lesinurad with Allopurinol in Inadequate Responders studies,1 Dr Singh provides a thorough overview of the phase 3 trials demonstrating the efficacy and safety of lesinurad given in combination with allopurinol for the treatment of gout in patients who do not reach serum uric acid goal on …
Contributors Both authors contributed to the writing of this letter to the editor.
Funding Funding was provided by Ironwood Pharmaceuticals.
Competing interests RV and BS are employees of Ironwood Pharmaceuticals.
Provenance and peer review Not commissioned; internally peer reviewed.